➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
Harvard Business School
Express Scripts
Medtronic

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,168,620


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,168,620 protect, and when does it expire?

Patent 8,168,620 protects DYMISTA and is included in one NDA.

Protection for DYMISTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-six patent family members in twenty-seven countries.

Summary for Patent: 8,168,620
Title:Combination of azelastine and steroids
Abstract: A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.
Inventor(s): Lulla; Amar (Mumbai, IN), Malhotra; Geena (Mumbai, IN)
Assignee: CIPLA Limited (Mumbai, IN)
Application Number:10/518,016
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,168,620
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use; Composition; Process;

Drugs Protected by US Patent 8,168,620

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan Speciality Lp DYMISTA azelastine hydrochloride; fluticasone propionate SPRAY, METERED;NASAL 202236-001 May 1, 2012 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,168,620

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0213739.6Jun 14, 2002
PCT Information
PCT FiledJune 13, 2003PCT Application Number:PCT/GB03/02557
PCT Publication Date:December 24, 2003PCT Publication Number: WO03/105856

International Family Members for US Patent 8,168,620

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 428428 ⤷  Try it Free
Australia 2003244799 ⤷  Try it Free
Australia 2009243420 ⤷  Try it Free
Australia 2009243422 ⤷  Try it Free
Brazil 0312128 ⤷  Try it Free
Brazil 122014030158 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Harvard Business School
Colorcon
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.